# A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years

> **NCT07178522** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Medigen Vaccine Biologics Corp.** · enrollment: 378 (estimated)

## Conditions studied

- Enterovirus 71 Inactivated Vaccine

## Interventions

- **BIOLOGICAL:** Envacgen®

## Key facts

- **NCT ID:** NCT07178522
- **Lead sponsor:** Medigen Vaccine Biologics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 378 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07178522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07178522, "A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07178522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*